Аутори:
1. Бојан Павичар, Аффидеа, Интернационални медицински центар, Центар за Радиотерапију, Дванаест беба бб, Бања Лука, Пр, Republic of Srpska, Bosnia and Herzegovina
2. Andrej Milosavljević, Center for Radiation Therapy, International Medical Centers, Affidea, Banja Luka, Bosnia and Herzego, Republic of Srpska, Bosnia and Herzegovina
3. Milomir Milaković, Center for Radiation Therapy, International Medical Centers, Affidea, Banja Luka, Bosnia and Herzego, Republic of Srpska, Bosnia and Herzegovina
4. Tatjana Ignjić, IMC Banja Luka - Affidea, Republic of Srpska, Bosnia and Herzegovina
5. Petar Janjic, IMC Banja Luka, Republic of Srpska, Bosnia and Herzegovina
6. Mihajlo Tovilović, Center for Radiation Therapy, International Medical Centers, Affidea, Banja Luka, Bosnia and Herzego, Republic of Srpska, Bosnia and Herzegovina
7. Горан Коларевић, Republic of Srpska, Bosnia and Herzegovina
8. Драгољуб Мирјанић, Академија наука и умјетности Републике Српске, Republic of Srpska, Bosnia and Herzegovina

Апстракт:
This study compares the dosimetric effects of the American Association of Physicists in Medicine (AAPM) TG-43 dose formalism and the Acuros BV (grid-based Boltzmann solver, GBBS) formalism on high-dose-rate (HDR) brachytherapy planning for cervical cancer patients treated with a tandem and ring applicator. Ten cervical cancer patients were included in the study. The high-risk clinical target volume (HR-CTV) and organs at risk (OARs) were delineated using computed tomography (CT) imaging and manual contouring methods. The doses to HR-CTV were assessed using D50%, D90%, and D98% metrics, while for OARs, D2cc doses were compared. For HR-CTV, the dose differences between TG-43 and Acuros BV were as follows: D50% (1.9%), D90% (2.6%), and D98% (3.4%). For OARs, the D2cc dose differences were: bladder (3.0%), rectum (2.6%), small bowel (2.8%), and sigmoid colon (2.9%). Overall, the study demonstrates that while both TG-43 and Acuros BV formalisms provide comparable dosimetric outcomes for HDR brachytherapy of cervical cancer, Acuros BV offers slight dose reductions across HR-CTV and OARs. The differences in dosimetric parameters between TG-43 and Acuros BV are statistically significant (p=0.05), but their clinical significance has yet to be examined.

Кључне речи:
HDR Brachytherapy,Cervical Cancer,TG-43 Algorithm,Acuros BV,Dosimetry

Тематска област:
СИМПОЗИЈУМ Б - Биоматеријали и наномедицина

Датум пријаве сажетка:
15.07.2024.

Конференцијa:
Contemporary Materials 2024 - Savremeni Materijali

Сажетак рада